---
document_datetime: 2023-09-21 20:34:37
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_en.pdf
document_name: bylvay-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.4635494
conversion_datetime: 2025-12-18 10:58:10.813474
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| EMA Number       | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/21/1566/001 | Bylvay            | 200 µg     | Capsule, hard         | Oral use                  | Bottle (HDPE)         | 30 capsules |
| EU/1/21/1566/002 | Bylvay            | 400 µg     | Capsule, hard         | Oral use                  | Bottle (HDPE)         | 30 capsules |
| EU/1/21/1566/003 | Bylvay            | 600 µg     | Capsule, hard         | Oral use                  | Bottle (HDPE)         | 30 capsules |
| EU/1/21/1566/004 | Bylvay            | 1200 µg    | Capsule, hard         | Oral use                  | Bottle (HDPE)         | 30 capsules |

## Annex IV

Conclusions on the granting of the marketing authorisation under exceptional circumstances presented by the European Medicines Agency

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## Conclusions presented by the European Medicines Agency on:

## · Marketing authorisation under exceptional circumstances

The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the marketing authorisation under exceptional circumstances as further explained in the European Public Assessment Report.